The leader in the development of stable, alcohol-free, topical foam delivery systems for dermatology and other topical applications- Ness Ziona, Isarael-based Foamix, Ltd. – has licensed a novel topical foam product, PerFoam™ 1% for the contemporary treatment of head lice to Taro Pharmaceutical Industries Ltd. (
PerFoam™ 1%’s active ingredient, permethrin, is the recommended compound for the treatment of lice by the
The terms of agreement include Foamix transferring the technology to Taro and Taro will upscale, manufacture, register and commercialize PerFoam™ 1% for distribution in Israel and the
The financial terms of the agreement were not disclosed, thought the product is expected to be launched in late 2008.
Find more details for the press release.
Comment Preview